Medical applications of dextran and its derivatives

Polysaccharides in Medicinal Applications

Volumn , Issue , 2017, Pages 505-523

  de Beider, Anthony N ^a  

^a TdB Consultancy AB   (Sweden)

Author keywords

[No Author keywords available]

Indexed keywords

MEDICAL APPLICATIONS;

CLINICAL TRIAL; DEXTRAN SOLUTIONS; MEDICAL RESEARCH; PLASMA EXPANDERS;

DEXTRAN;

EID: 85052601694     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1201/9780203742815     Document Type: Chapter

References (219)

1. Dextran, Pharmacia, Uppsala, Sweden, 1990.
2. Properties and Applications of Dextrans, Acta Academiae Regiae Scientiarum Upsaliensis, 12, Almquist and Wiksell, Stockholm, 1969.
3. A. N. de Belder, Dextran, in Industrial Gums (R. Whistler, ed.), Academic Press, New York, 1993, p. 399.
4. U. F. Gruber, Blood Replacement, Springer-Verlag, Berlin, 1969, p. 55.
5. S. Bygdeman, Properties and indications for the use of dextran, Middle East J. Anaesth., 2, 1 (1970).
6. Dextrans: Current Concepts of Basic Actions and Clinical Applications, C. C. Thomas, Springfield, 111., 1971.
7. N. W. H. Cheetham, E. Fiala-Beer, and G. W. Walker, Dextran, structural details from high-field proton NMR spectroscopy, Carbohydr. Res., 14, 149 (1991).
8. F. R. Send, N. N. Hellman, N. H. Ludwig, G. E. Babcock, R. Tobin, C. A. Glass, and B. L. Lamberts, Viscosity, sedimentation and light-scattering properties of fractions of an acid-hydrolysed dextran, J. Polym.Sci., 77, 527 (1955).
9. J. Sabatie, L. Choplin, M. Moan, J. L. Doublier, F. Paul, and P. Monsan, The effect of synthesis temperature on the structure of dextran NRRL B512F, Carbohydr. Polymers, 9, 87 (1988).
10. T. Kuge, K. Kobayashi, S. Kitamura, and H. Tanahashi, Degrees of long chain branching in dextrans, Carbohydr. Res., 160, 205 (1987).
11. K. A. Granath, Solution properties of branched dextrans, J. Colloid Sci., 13, 308 (1958).
12. F. Carrasco, E. Chornet, R. P. Overend and J. Costa, A generalized correlation for the viscosity of dextrans in aqueous solutions as a function of temperature, concentration and molecular weight at low shear rates, J. Appl. Polym. Sci., 37, 2087 (1989).
13. G. Arturson and G. Wallenius, The renal clearance of dextran of different molecular sizes in normal humans, Scand. J. Clin. Lab. Invest., 16, 81 (1964).
14. D. S. Rowe, Colloid osmotic pressures of dextran, serum and dextran-serum mixtures, Nature, 175, 554(1955).
15. A. M. Basedow and K. H. Ebert, Production, characterization, and solution properties of dextran fractions of narrow molecular weight distributions, J. Polym. Sci. Polym. Symp., 66, 101 (1979).
16. M. P. Bohrer, G. D. Patterson, and P. J. Carroll, Hindered diffusion of dextran and ficoll in microporous membranes, Macromol., 17, 1170(1984).
17. A. Gronwall, Dextran and Its Use in Colloidal Infusion Solutions, Almqvist and Wiksell, Stockholm, 1957, p. 73.
18. R. Squire, J. P. Bull, W. d’A Maycock and C. R. Ricketts, Dextran, Its Properties and Use in Medicine, Blackwell, Oxford, 1955.
19. A. Segal, The Clinical Use of Dextran Solutions, Grune and Stratton, New York and London, 1964.
20. R. Terry, A. Golodetz, C. E. Philips and R. R. White, Metabolism of dextran-a plasma volume expander: studies of radioactive carbon-labelled dextran in dogs, J. Lab. Clin. Med., 42, 6 (1953).
21. E. L. Rosenfeld and I. S. Lukomskaja, The splitting of dextran and isomaltose by animal tissues, Clin. Chim.Acta, 2, 105 (1957).
22. R. Ammon, Das Vorkommen von dextranase im menschlichen Gewebe, Enzymologia, 25, 245 (1963).
23. P. A. Turner and W. d’A Maycock, Distribution of injected dextran in the mouse, J. Pathol. Bacterioi, 75, 145 (1958).
24. E. L. Rosenfeld and A. S. Saienko, Metabolism in vivo of clinical dextran, Clin. Chim. Acta, 10, 223 (1964).
25. M. A. Dubick, B. A. Ryan, J. L. Summary, and C. E. Wade, Dextran metabolism following infusion of 7.5% NaCl/6% dextran 70 to euvolemic and hemorrhaged rabbits, Drug Dev. Res., 25, 29 (1992).
26. O. Tangen and H. Hint, unpublished studies, Pharmacia, Uppsala, 1967.
27. A. Jeanes, Digestibility of food polysaccharides by man: a review, in Physiological Effects of Food Carbohydrates (A. Jeanes and J. Hodge, ed.), American Chemical Society, Washington, D.C. 1975, p. 336.
28. T. M. Parkinson, Metabolism of orally administered dextran and Sephadex in rats, Nature, 215, 415 (1967).
29. W. L. Bloom and A. E. Wilhelmi, Dextran as a source of liver glycogen and blood reducing substance, Proc. Soc. Exp. Biol. Med., 81, 501 (1952).
30. Fed. Reg. 42: FR 59518-21 (Nov. 18, 1977).
31. H. Hint, The pharmacology of dextran and physiological background for the clinical use of Rheo-macrodex and Macrodex, Acta Anaesthesiol. Belg., 119 (1968).
32. H. Hint, Relationships between the chemical and physicochemical properties of dextran and its pharmacological effects, in Dextrans (J. R. Derrick and M. M. Guest, eds.), C. C. Thomas, Springfield, 111., 1971, p. 3.
33. A. Grönwall and B. Ingelman, Untersuchungen uber Dextran und sein Verhalten bei parenteraler Zu-fuhr, Acta Physiol. Scand., 9, 1 (1945).
34. G. Thorsén and H. Hint, Aggregation, sedimentation and intravascular sludging of erythrocytes, Acta Chir. Scand, Suppi, 154, 1 (1950).
35. W. Richter, Normalising effect of low molecular dextran weight fractions on the reduced suspension stability of human erythrocytes in vitro, Acta Chir. Scand., 131, 1 (1966).
36. J. Engeset, A. L. Stalker and N. A. Matheson, Effects of dextran 40 on red cell aggregation in rabbits, Cardiovasc. Res., 1, 379 (1967).
37. C. R. Ricketts, Interaction of dextran and fibrinogen, Nature, 169, 970 (1952).
38. F. Fletcher, L. E. Martin, and A. H. Ratcliffe, Interaction of macromolecules and fibrinogen, Nature, 170, 319 (1952).
39. J. Krøll and R. Dybkaer, In vitro precipitations in plasma by low molecular weight dextran, Scand. J. Clin. Lab. Invest., 16, 31 (1964).
40. R H. Iverius and T. C. Laurent, Precipitation of some plasma proteins by the addition of dextran or polyethylene glycol, Biochim. Biophys. Acta, 133, 371 (1967).
41. T. C. Laurent, The interaction between polysaccharides and other macromolecules. 5. The solubility of proteins in the presence of dextran, Biochem. J., 89, 253 (1963).
42. U. Jacobaeus, Studies on the effect of dextran on the coagulation of blood, Acta Med. Scand. Suppl., 322, 5 (1957).
43. S. E. Bergentz, O. Eiken, and I. M. Nilsson, The effect of dextran of various molecular weights on the coagulation in dogs, Thromb. Diath. Hemorrh., 11, 15 (1961).
44. M. Åberg, On effect of dextran on lysability and structure of ex vivo thrombi, platelet function and factor VIII, Dissertation, Malmo General Hospital, University of Lund, Malmö, 1978.
45. M. Keler-Bacŏka and Z. Pučar, Lipid changes caused by colloidal dextran added to human sera in different volume ratios, Clin. Chim. Acta, 14, 24 (1966).
46. P. H. Iverius, Solubility of low density (B) lipoproteins in the presence of dextran, Clin. Chim. Acta, 20, 261 (1968).
47. A. Laurell, Influence of dextran on the conversion of fibrinogen to fibrin, Scand. J. Clin. Lab. Invest., 3, 262(1951).
48. G. Carlin, K. O. Wik, K. E. Arfors, T. Saldeen, and O. Tangen, Influences on the formation and structure of fibrin, Thromb. Res., 9, 623 (1976).
49. T. B. Muzaffar, G. B. Youngson, W. A. J. Bryce, and D. P. Dhall, Studies on fibrin formation and effects of dextran, Thromb. Diath. Hemmorrh., 28, 244 (1972).
50. S. Shulman and J. D. Ferry, The conversion of fibrinogen on clotting time and clot opacity, J. Phys. Colloid Chem., 54, 66 (1950).
51. U. Abildgaard, Acceleration of fibrin polymerisation by dextran and ficoll: interaction with calcium and plasma proteins, Scand. J. Clin. Lab. Invest., 18, 518 (1966).
52. M. Fischer and H. Wimmer, Aktivierung des fibrinolytischen Systems durch niedermolekulares Dextran, Bibl. Haemat., 23, 1278 (1965).
53. M. Åberg, S. E. Bergentz and U. Hedner, The effect of dextran on the lysability of ex vivo thrombi, Ann. Surg., 181, 342 (1975).
54. G. Carlin and N. U. Bang, Enhancement of plasminogen activation and purified clot lysis by dextran 70, Thromb. Res., 19, 535 (1980).
55. 2-plasmin inhibitor), Thromb. Res., 12, 681 (1978).
56. G. Carlin, Effect of dextran of fibrinolysis, Dissertation, Uppsala University, Uppsala, 1980.
57. G. Carlin, J. Modig, and T. Saldeen, Effect of infusion of Dextran 70 on fibrinolysis inhibition activity in human serum, Acta Chir. Scand., 145, 129 (1979).
58. I. A. M. Wallenbeck and O. Tangen, On the lysis of fibrin formed in the presence of dextran and other macromolecules, Thromb. Res., 6, 75 (1975).
59. E. Deutsch, Die Anticoagulantien in der Therapie der peripheren arteriellen Durchblutungstorungen, Wien Klin. Wochenschr., 76, 151 (1964).
60. M. Eriksson, T. Saldeen, and R. Wallin, Effect of dextran on plasma tissue plasminogen-activator and tissue plasminogen activator inhibitor during surgery, Thromb. Haemostas., 62, 394 (1989).
61. J. Perttila, M. Salo, and O. Peltola, Effects of different plasma substitutes on plasma fibronectin concentrations in patients undergoing abdominal surgery, Acta Anaesthesiol. Scand., 34, 304 (1990).
62. B. Alexander, K. Odake, D. Lawlor, and M. Swanger, Coagulation, hemostasis and plasma volume expanders: a quarter century enigma, Fed. Proc, 34, 1429 (1975).
63. M. Åberg, U. Hedner, and S. E. Bergentz, Effect of dextran on factor VIII and platelet function, Ann. Surg., 189, 243 (1979).
64. P. N. Bennet, D. P. Dhall, F. N. McKenzie, and N. A. Matheson, Effects of dextran infusion on the adhesiveness of human blood platelets, Lancet, ii, 1001 (1966).
65. S. Bygdeman, R. Eliasson, and B. Gullbring, Effect of dextran infusion on the adenosine diphosphate induced adhesiveness and the spreading capacity of human blood platelets, Thrombos. Diathes. Haem-orrh., 15, 451 (1966).
66. W. L. Bloom, D. S. Harmer, M. F. Bryant, and S. S. Brewer, Coating of vascular surfaces and cells: a new concept in prevention of intravascular thrombosis, Proc. Soc. Exp. Biol. NY, 115, 384 (1964).
67. S. Rothman, E. Adelson, A. Schwebel, and R. D. Langdell, Adsorption of C-14 dextran to human blood platelets and red blood cells in vitro, Vox Sang., 2, 104 (1957).
68. A. L. Baldwin, N. Z. Wu, and D. L. Stein, Endothelial surface charge of intestinal mucosal capillaries and its modulation by dextran, Microvasc. Res. 42, 160 (1991).
69. A. Cudd, T. Arvinte, B. Schultz, and C. Nicolau, Dextran protection of erythrocytes from low-pH induced hemolysis, FEBS, 250, 293 (1989).
70. S. Chien, Physiological and pathophysiological significance of hemorheology, in Clinical Hemorhe-ology (S. Chien, J. Dormandy, E. Ernst, and A. Matrai, eds.), Nijhoff, Boston, 1987, p. 125.
71. C. Thierjung, M. Menger, F. U. Sack, T. J. Galla, and K. Messmer, The effect of prophylactic iso-volemic hemodilution on the PMN-endothelium interaction in postischemic skeletal muscle, Int. J. Microcirc. Clin. Exp., Special issue, 69 (1988).
72. S-R. Lin, M. O’Connor, A. King, P. Harnish, and H. W. Fischer, Effect of dextran on cerebral function and blood flow after cardiac arrest, Stroke, 10, 13 (1979).
73. C. H. Haljamae, Volume substitution in shock, Acta Anaesthesiol. Scand., 37 (Suppl. 98), 25 (1993).
74. E. A. Kabat and A. E. Bezer, The effect of variation in molecular weight on the antigenicity of dextran in man, Arch. Biochem. Biophys., 78, 306 (1958).
75. W. Richter and L. Kagedal, Preparation of dextran-protein conjugates and studies of their immunogenicity, Int. Arch. Allergy, 42, 887 (1972).
76. E. A. Kabat, The upper limit for the size of the human anti-dextran combining site, J. Immunol, 84, 82 (1960).
77. E. A. Kabat, Experimental Immunochemistry (E. A. Kabat and M. Meyer, ed.), 2nd ed., Thomas, Springfield, 1961, p. 241.
78. W. Richter, Hapten inhibition of passive dextran antidextran anaphylaxis in guinea pigs: the role of molecular size in anaphylactogenicity and precipitability of dextran fractions, Int. Arch. Allergy Appl. Immunol., 41, 826(1971).
79. A. Grönwall and B. Ingelman, The introduction of dextran as a plasma substitute, Vox Sang., 47, 96 (1984).
80. R. J. Dimler, Dextran helps save lives, Yearbook Agric, 3612, 314 (1968).
81. L. Thorén, Dextran as a plasma volume substitute, Prog. Clin. Biol. Res., 19, 265 (1978).
82. World Health Organisation, The use of essential drugs, Technical Report Series 685, WHO, Geneva, 1983.
83. U. F. Gruber and J. Siegrist, Der Volumeneffekt verschiedener Plasmaersatzstoffe, Arch. Klin. Chir., 301, 128 (1962).
84. A. Bergman, M. Andreen, and M. Blombaeck, Plasma substitution with 3% dextran 60 in orthopedic surgery: influence on plasma colloid osmotic pressure, coagulation parameters, immunoglobulins and other plasma constituents, Acta Anaesthesiol. Scand., 34, 21 (1990).
85. The Role of Hemodilution in Optimal Patient Care, (R. F. Tuma, J. V. White, and K. Messmer, eds.), W. Zuckschwerdt Verlag, Munchen, 1989.
86. L-E. Gelin and B. Ingelman, Rheomacrodex: a new dextran solution for rheological treatment of impaired capillary flow, Acta Chir. Scand., 122, 294 (1961).
87. L-E. Gelin, Rheologic disturbances and the use of low viscosity dextran in surgery, Rev. Surg., 19, 385 (1962).
88. L-E. Gelin, Studies on anemia of injury, Dissertation, University of Lund, 1956.
89. M. I. Gregersen, B. Peric, S. Usami, and S. Chien, Relation of molecular weight of dextran to its effects on viscosity and sedimentation rate of blood, BibliothecaAnat., 4, 58 (1964).
90. D. Nolte, A. Illner, M. D. Menger, and K. Messmer, Reduction of post-ischemic leukocyte-endothelium interaction by dextran 70 but not by hydroxyethyl-starch 200/0.62, Int. J. Microcirc. Clin. Exp., 11, 203 (1992).
91. S. Borgström, L-E. Gelin, and B. Zederfeldt, The formation of vein thrombi following tissue injury, Acta Chir. Scand., Suppi, 247 (1959).
92. L. J. L. Koekenberg, Experimental use of Macrodex as a prophylaxis against post-operative thromboembolism, Bull. Soc. Int. Chir., 21, 501 (1962).
93. S. Bygdeman, ed., Thrombotic diseases with reference to the use of dextrans, Acta Chir. Scand., Suppl., 387,1967.
94. K-G. Ljungström, The antithrombotic efficacy of dextran, Acta Chir. Scand., 543, (Suppl.), 26 (1988).
95. P. A. Flordal and K-G., Ljungström, Dextran vid total hoftplastikoperation, Droppjournalen, 4, 3 (1992).
96. M. Rocha e Silva, Jr., Hypertonic NaCl treats hemorrhagic shock: other sodium salts are also effective, Proceedings of I Reuniao Anual da Federacao das Sociedades de Biologia Experimental, University of Sao Paulo, 1986, p. 138.
97. G. J. Smith, G. C. Kramer, P. Perron, S. Nakayama, R. A. Gunther, and J. W. Holcroft, A comparison of several hypertonic solutions for resuscitation of bled sheep, J. Surg. Res., 39, 517 (1985).
98. P. A. Maningas and P. A. Bellamy, Small volume infusion of 7.5% NaCl in 6% dextran 70 for the treatment of severe hemorrhagic shock in swine, Ann. Emerg. Med., 75, 1131 (1986).
99. K. Mattox, P. Maningas, E. E. Moore, J. R. Mateer, J. Marx, C. Aprahamian, J. M. Burch, and P. E. Pepe, Prehospital hypertonic saline/dextran infusion for post-traumatic hypotension, the U.S.A. Multicenter Trial, Ann. Surg., 213, 482 (1991).
100. H. Hedin and W. Richter, Pathomechanisms of dextran-induced anaphylactoid/anapylactic reactions in man, Int. Arch. Allergy Appl. Immunol, 62, 122 (1982).
101. D. Kraft, H. Hedin, W. Richter, O. Schneider, H. Rumpold, and M. E. Devey, Immunoglobulin class and subclass distribution of dextran-reactive antibodies in human reactors and non reactors to clinical dextran, Allergy, 37, 481 (1982).
102. K. Messmer, K-G. Ljungström, U-F. Griiber, W. Richter and H. Hedin, Prevention of dextran-induced anaphylactoid reactions by hapten inhibition, Lancet, 7, 975 (1980).
103. K-G. Ljungström, H. Renck, H. Hedin, W. Richter, and B. Rosberg, Prevention of dextran-induced anaphylactoid reactions by hapten inhibition. I. A. Scandinavian Multicenter Study on the effects of 10 ml dextran 1, 15% administered before dextran 70 or dextran 40, Acta Chir. Scand., 149, 341 (1983).
104. W. Richter and H. Hedin, Dextran hypersensitivity, Immunol. Today, 3, 132 (1982).
105. K-G. Ljungström, Safety of dextran in relation to other colloids: ten years experience with hapten inhibition, Infusionsther., 20, 206 (1993).
106. R. Schlumpf, P. Morel, J. J. Loveras, R. M. Condie, A. Matas, J. Kurle, C. G. Fasola, J. S. Najarian, and D. E. R. Sutherland, Dextran 40 successfully replaces the non-essential hydroxyethylstarch in the University of Wisconsin solution for 72-hour simple cold storage of the canine kidney, Transplantation Proc, 23, 657(1991).
107. B. O. Howden, P. Jablonski, A. C. Thomas, K. Walls, M. Biguzas, D. F. Scott, H. Grossman, and V. C. Marshall, Liver preservation with UW solution. I. evidence that hydroxyethylstarch is not essential, Transplantation, 49, 869 (1990).
108. N. V. Jamieson, S. Lindell, R. Sundberg, J. H. Southard, and F. O. Belzer, Evaluation of simplified variants of the UW solution using the isolated perfused rabbit liver, Transplant. Proc, 21, 1294(1989).
109. S. Miyoshi, S. Shimokawa, H. Schreinemakers, H. Date, W. Weder, B. Harper, and J. D. Cooper, Comparison of the University of Wisconsin preservation solution and other crystalloid perfusates in a 30 hour rabbit lung preservation model, J. Thorac. Cardiovasc. Surg., 103, 27 (1992).
110. A. Steen, T. Sjoberg, G. Massa, L. Ericsson, and L. Lindberg, Safe preservation for 12 hours with low potassium dextran solution, Ann. Thorac. Surg., 55, 434 (1993).
111. P. Morel, A. Moss, R. Schlumpf, R. Nakhleh, J. K. Lloveras, M. J. Field, R. Condie, A. J. Matas, and D. E. Sutherland, 72-Hour preservation of canine pancreas: successful replacement of hydroxyethylstarch by dextran in UW solution, Transplant. Proc, 24, 791 (1992).
112. M. Reim, R. Hesse, and G. Pietruscka, Über den Stoffwechsel von Organkulturen der Cornea in TC 199 mit Zusatz von Dextran 500 oder HAES 450, Klin. Monatsbl. Augenheilk., 196, 76 (1990).
113. E. Pels and Y. Schuchard, Organ culture preservation of human corneas, Doc. Ophthalmol., 56, 147 (1983).
114. H. J. L. Van der Want, E. Pels, Y. Schuchard, B. Olsen, and S. Sperling, Electron microscopy of cultured human corneas: osmotic hydration and the use of a dextran fraction (Dextran T500) in organ culture, Arch. Ophthalmol., 101, 1920 (1983).
115. R. K. Reed, P. Lilleaasen, H. Lindberg, and O. Stokke, Dextran 70 versus donor plasma as colloid in open-heart surgery, Scand. J. Clin. Lab. Invest., 45, 269 (1985).
116. H. K. Amin and R. S. Neuwirth, Operative hysteroscopy utilizing dextran as distending medium, Clin. Obstet. Gynecol, 26, 277 (1983).
117. P. J. Taylor, D. Lewinthal, A. Leader, and H. A. Pattinson, A comparison of Dextran 70 with carbon dioxide as the distending medium for hysteroscopy in patients with infertility or requesting reversal of a prior tubal sterilisation, Fertil. SteriL, 47, 861 (1987).
118. A. Pellicer and M. P. Diamond, Distending media for hysteroscopy, Obstet. Gynecol. Clin. North Am., 15, 23 (1988).
119. R. E. Blackwell and J. B. Younger, Inhibition of peritoneal adhesion re-formation after lysis with thirty-two percent dextran 70, Fertil. SteriL, 35, 592 (1981).
120. S. M. Rosenberg, Dextran 70: encouraging early clinical studies, Prog. Clin. Biol. Res., 358, 157 (1990).
121. E. Ricaurte and T. W. Hilgers, Safety of intraperitoneal 32% dextran 70 as an antiadhesion adjuvant, J. Reprod. Med, 34, 535 (1989).
122. E. London and G. D. Twigg, British patent 748,024 (1956).
123. J. S. G. Cox, G. R. Kennedy, J. King, P. R. Marshall, and D. Rutherford, Structure of an iron-dextran complex, J. Pharm. Pharmacol, 24, 513 (1972).
124. E. Kolb and U. Hofmann, The most suitable form of administration of iron dextran to piglets, its utilisation and mechanism of possible toxicity: a review. Monatsh. Veterinaermed., 44, 497 (1989).
125. P. Geisser, H. Hohl, M. Baer, H. Heim, and W. Fischer, Investigation of the dosage efficacy relationship of iron dextran in veal calves, Arzneim. Forsch., 41, 32 (1991).
126. V. J. Kumpf and E. G. Holland, Parenteral iron dextran therapy, DICPAnn. Pharmacother., 24, 162 (1990).
127. M. Auerbach, D. Witt, W. Toler, M. Fierstein, R. G. Lerner, and H. Ballard, Clinical use of the total dose intravenous infusion of iron dextran, J. Lab. Clin. Med., III, 566 (1988).
128. J. A. Norton, M. L. Peters, R. Wesley, M. M. Maher, and M. F. Brennan, Iron supplementation of total parenteral nutrition: a prospective study, J. Parenter. Enteral Nutr., 7, 457 (1983).
129. J. W. M. Bulte, M. W. A. de Jonge, R. L. Kamman, K. G. Go, F. Zuiderveen, B. Blaauw, J. A. Oost-erbaan, T. H. The, and L. de Leij, Dextran magnetite particles contrast-enhanced MRI of blood-brain barrier disruption in a rat model. Magn. Reson. Med., 23, 215 (1992).
130. D. L. White, K. P. Aicher, A. A. Tzika, J. Kucharczyk, B. L. Engelstad, and M. E. Moseley, Iron dextran as a magnetic susceptibility contrast agent flow related contrast effects in the T2-weighted spin-echo MRI of normal rat and cat brain, Magn. Reson. Med., 24, 14 (1992).
131. R. L. Magin, G. Bacic, M. R. Niesman, J. C. Alameda, Jr., S. M. Wright, and H. M. Swartz, Dextran magnetite as a liver contrast agent, Magn. Reson. Med., 20, 1 (1991).
132. A. Iannone, R. L. Magin, T. Walczak, M. Federico, H. M. Swartz, A. Tomasi, and V. Vannini. Blood clearance of dextran magnetite particles determined by a noninvasive ESR method, Magn. Reson. Med., 22, 435(1991).
133. Y. Anzai, K. E. Blackwell, S. L. Hirschowitz, J. W. Rogers, Y. Sato, W. T. C. Yuh, V. M. Runge, M. R. Morris, S. J. McLachlan, and R. B. Lufkin, Initial clinical experience with dextran-coated superparamagnetic iron oxide for detection of lymph node metastases in patients with head and neck cancer, Radiology, 192, 709 (1994).
134. Y. Anzai, S. McLachlan, R. Saxton, M. Morris, and R. B. Lufkin, Dextran-coated superparamagnetic iron oxide, the first human use of a new MR contrast agent for assessing lymph nodes in the head and neck, Am. J. Neuroradioi, 15, 87 (1994).
135. T. C. Winter, R C. Freeny, H. V. Nghiem, L. A. Mack, R. M. Patten, C. R. Thomas, and S. Elliot, MR imaging with IV superparamagnetic iron oxide: efficacy in the detection of focal hepatic lesions, Am. J. Roentgenol., 161, 1191 (1993).
136. K. C. P. Li, R. G. Quisling, F. E. Armitage, D. Richardson, and C. Mladinich, In vivo MR evaluation of gadolinium DTPA conjugated to dextran in normal rabbits, Magn. Reson. Imaging, 10, 439 (1992).
137. S. C. Wang, M. G. Wikstrom, D. L. White, J. Klaveness, E. Holtz, P. Rongved, M. E. Moseley, and R. C. Brasch, Evaluation of gadolinium DTPA-labelled dextran as an intravasular contrast agent imaging characteristics in normal rat tissues, Radiology, 175, 483 (1990).
138. P. V. Kulkarni, P. Antich, B. Govanella, and D. F. Ranney, Evaluation of polymeric gadolinium-DTPA dextran T70 as an MRI tumor enhancing agent for human bro melanomas in nude mice, J. Nucl. Med., 28, 704 (1987).
139. E. Henze, H. R. Schelbert, J. D. Collins, A. Najafi, J. R. Barrio, and L. R. Bennet, Lymphoscintigraphy with Tc-99m-labeled dextran, J. Nucl. Med., 23, 923 (1982).
140. N. H. Agha, A. M. Al-Hilli, N. D. Dahir, and A. M. Al-Nahhas, Technetium-99m dextran kit: formulation and biological behaviour, J. Radioanal. Nucl. Chem., 132, 11 (1989).
141. A. Gronwall, B. Ingelman, and H. Mosimann, A dextran sulphuric acid ester with heparin activity, Uppsala Lakarfdrening Fork, 51, 397 (1945).
142. C. R. Ricketts and K. W. Walton, Dextran sulphate: the relation of molecular features to biological properties, Br. J. Pharmacol., 8, 476 (1953).
143. P. Hjort, H. Stormorken, and O. Gilje, A study of the in vitro and in vivo effects (in man) of a synthetic heparin-like anticoagulant: dextran sulphate, Scand. J. Clin. Lab. Invest. [Suppl], 9, 29 (1957).
144. H. C. Hint and A. W. Richter, Chronic toxicity of dextran sulphate in rabbits, Br. J. Pharmacol, 13, 109 (1958).
145. D. Gemsa, M. Seitz, W. Kramer, G. Till, and K. Resch, The effects of phagocytosis, dextran sulphate and cell damage of PGEi sensitivity and PGEi production of macrophages, J., Immunol, 120, 1187(1978).
146. H. Hahn and M. Bierther, Morphological changes induced by dextran sulphate 500 in mononuclear phagocytes of Listeria-infected mice, Infect. Immun., 10, 1110 (1974).
147. M. C. Kielian, R. C. Steinman, and Z. A. Cohn, Intralysosomal accumulation of polyanions. I. Fusion of pinocytic and phagocytic vacuoles with secondary lysosomes, J. Cell Biol, 93, 866 (1982).
148. H. U. Schorlemmer, R. Burger, W. Hylton and A. C. Allison, Induction of lysosomal enzyme release from cultured macrophages by dextran sulphate, Clin. Immunol. ImmunopathoL, 7, 88 (1977).
149. S. A. Minchin, D. Leitenberg, L. L. Stunz, and T. L. Feldbush, Polyclonal activation of rat B cells. II. Dextran sulfate as a cofactor in mitogen-induced and antigen induced differentation of rat B lymphocytes, J. Immunol, 145, 2427 (1990).
150. G. D. Wetzel and J. R. Kettman, Activation of murine B lymphocytes. III. Stimulation of B lymphocyte clonal growth with lipopolysaccharide and dextran sulphate, J. Immunol, 126, 723 (1981).
151. E. Ruuth, I. Couillin, A. Herbelin, and F. Praz, Functional bioassay for B cell growth factors using polyclonally activated murine spleen B cells, Lymphokine Res., 8, 147 (1989).
152. J. Kettman, A. Soderberg, and I. Lefkovits, Activation/suppression of the immune response in vitro by antigen and dextran sulfate. 2. The role of T-cell subsets determined by cell separation and partition analysis, Cell. Immunol, 88, 129 (1984).
153. R. Burger, U. Hadding, H. U. Schlorlemmer, V. Brade and D. Bitter-Suermann, Dextran sulphate: a synthetic activator of C3 via the alternative pathway, Immunol, 29, 549 (1975).
154. M. Kishima, R. F. Ross and C. Kuniyasu, Cell-mediated and humoral immune response to Mycoplasma hyopneumoniae in pigs enhanced by dextran sulfate, Am. J. Vet. Res., 46, 456 (1985).
155. L. A. Hilgers, H. Snippe, M. Janze and J. M. Willers, Combinations of two synthetic adjuvants: synergistic effects of a surfactant and a polyanion on the humoral immune response, Cell. Immunol., 92, 203 (1985).
156. D. L. Watson, Serological response of sheep to live and killed staphylococcus aureus vaccines, Vaccine, 5, 275 (1987).
157. U. M. W. Kung, B. V. Goodger, G. R. Bushell, I. G. Wright, and D. J. Waltisbuhl, Vaccination of cattle with dextran sulphate binding babesia bigemina antigens, Int. J. Parasitol, 22, 621 (1992).
158. M. Ito, M. Baba, A. Sato, R. Pauwels, E. De Clerq, and S. Shigeta, Inhibitory effects of dextran sulphate and heparin on the replication of human immunodeficiency virus (HIV) in vitro, Antiviral Res., 7, 361 (1987).
159. R. Ueno and S. Kuno, Dextran sulfate, a potent anti-HIV agent in vitro having synergism with zidovudine, Lancet, 1, 1379 (1987).
160. M. Baba, R. Snoeck, R. Pauwels, and E. De Clerq, Sulfated polysaccharides are potent and selective inhibitors of various enveloped viruses, including Herpes Simples virus, cytomegalovirus, vesicular stomatitis virus, and human immunodeficiency virus, Antimicrob. Agents Chemother., 32, 1724 (1988).
161. D. C. Montefiori, W. E. Robinson, A. Modliszewski, J. M. Rowland, S. S. Schuffman, and W. M. Mitchell, Differential inhibition of HIV-1 cell binding and HIV-1 induced syncytium formation by low molecular weight sulphated polysaccharides, J. Antimicrob. Chemother., 25, 313 (1990).
162. D. I. Abrams, S. Kuno, R. Wong, K. Jeffords, M. Nash, J. B. Molaghan, R. Gorter, and R. Ueno, Oral dextran sulfate (UA001) in the treatment of acquired immunodeficiency syndrome (AIDS) and aids related complex, Ann. Intern. Med., 110, 183 (1989).
163. K. J. Lorentsen, C. W. Hendrix, J. M. Collins, D. M. Kornhauser, B. G. Petty, R. W. Klecker, C. Flexner, R. H. Eckel, and P. S. Lietman, Dextran sulfate is poorly absorbed after oral administration, Ann. Intern. Med., III, 561 (1989).
164. C. Flexner, P. A. Barditch-Crovo, D. M. Kornhauser, H. Farzadegan, L. J. Nerhood, R. E. Chaisson, K. M. Bell, K. J. Lorentsen, C. W. Hendrix, B. G. Petty and P. S. Lietman, Pharmacokinetics, toxicity and activity of intravenous dextran sulfate in human immunodeficiency virus infection, Antimicrob. Agents Chemother., 35, 2544 (1991).
165. N. R. Hartman, D. G. Johns, and H. Mitsuya, Pharmacokinetics analysis of dextran sulphate in rats as pertains to its clinical usefulness for therapy of HIV infection, AIDS Res. Hum. Retroviruses, 6, 805 (1990).
166. W. D. Comper, M. Tay, and J. Dawes, Desulphation of dextran sulphate during kidney ultrafiltration, Biochem. J., 297, 31 (1994).
167. I. Okayasu, S. Hatakeyamam, M. Yamada, T. Ohkusa, Y. Ingaki, and R. Nakaya, A novel method in the induction of reliable experimental acute and chronic ulcerative colitis in mice, Gastroenterology, 98, 694 (1990).
168. H. S. Cooper, S. N. Murthy, R. S. Shah, and D. J. Sedergran, Clinicopathologic study of dextran sulfate sodium experimental murine colitis, Lab. Invest., 69, 238 (1993).
169. A-C. Bylund-Fellenius, E. Landstrom, L-G. Axelsson, and T. Midtvedt, Experimental colitis induced by dextran sulphate in normal and germfree mice, Microb. Ecol, 7, 207 (1994).
170. T. Tamaru, H. Kobayashi, S. Kishimoto, G. Kajiyama, F. Shimamoto, and W. R. Brown, Histochem-ical study of colonic cancer in experimental colitis of rats, Dig. Dis. Sci., 38, 529 (1993).
171. I. Hirono, K. Kuhara, S. Hosaka, S. Tomizawa, and L. Goldberg, Induction of intestinal tumors in rats by dextran sulfate sodium, J. Natl. Cancer Inst., 66, 579 (1981).
172. M. Yamada, T. Ohkusa, and I. Okayasu, Occurrence of dysplasia and adenocarcinoma after experimental chronic colitis in hamsters induced by dextran sulphate sodium, Gut, 33, 1521 (1992).
173. Y. Homma, Y. Mikami, H. Tamachi, N. Nakaya, H. Nakamura, and Y. Goto, Comparison of selectivity of LDL removal by double filtration and dextran sulfate cellulose column plasmapheresis and changes in subfractionated plasma lipoproteins after plasmapheresis in heterozygous familial hypercholesterolemia, Metabolism, 36, 419 (1987).
174. A. Yamamoto, S. Kojima, M. S. Harada, A. Kawaguchi and K. Hatanaka, Assessment of the bio-compatability and long-term effect of LDL-apheresis by dextran sulfate-cellulose column, Art if. Organs, 16, 177 (1992).
175. P. Schulzeck, C. J. Olbricht, and K. M. Koch, Long term experience with extracorporeal low-density lipoprotein cholesterol removal by dextran sulfate cellulose adsorption, Clin. Invest., 70, 99 (1992).
176. P. Rubba, F. Faccenda, S. di Somma, A. Gnasso, N. Scarpato, A. Iannuzzi, G. Nappi, A. Postiglione, O. De Devitiis and M. Mancini, Cerebral blood flow velocity and systematic vascular resistance after acute reduction of low density lipoprotein in familial hypercholesterolemia, Stroke, 24, 1154 (1993).
177. F. Gubensek and S. Lapanje, Potentiometric titration studies of diethylaminoethyl-dextran base, J. Macromol. Sci. Chem., 2, 1045 (1968).
178. F. Galeone, F. Giuntoli, G. Brunelleschi, and P. Saba, Double-blind placebo controlled crossover study of DEAE-dextran in hyperlipoproteinemia secondary to non-insulin dependent diabetes melli-tus, Acta Ther., 16, 313 (1990).
179. G. Soldani, M. Maccheroni, F. Martelli, and G. Cardini, Biochemistry and pharmacology of diethylaminoethyl-dextran, Int. J. Obes., 11, 201 (1987).
180. I. Joo and J. Emod, Adjuvant effect of DEAE-dextran on cholera vaccines, Vaccine, 6, 233 (1988).
181. N. R. Fulton, Reproductive performance of ewes vaccinated with androstenedione 7 HS A in a DEAE-dextran adjuvant fecundin, Can. J. Anim. Sci., 68, 1322 (1988).
182. M. Hibma and J. F. T. Griffin, The effect of adjuvants on active and passive immunity in pregnant deer and their offspring, Vet. Immunol, lmmunopathoi, 31, 279 (1992).
183. K. J. Beh and A. K. Lascelles, The effect of adjuvants and prior immunization on the rate and mode of uptake of antigen into afferent popliteal lymph from sheep, Immunology, 54, 487 (1985).
184. R. M. Fox, J. F. Mynderse, and M. Goulian, Incorporation of deoxynucleotides into DNA by diethyl-aminoethyl dextran-treated lymphocytes, Biochemistry, 16, 4470 (1977).
185. C. J. Freau and R. C. Bleackley, Factors influencing transient expression in cytotoxic T cells following DEAE dextran-mediated gene transfer, Somat. Cell. Mol. Genet., 17, 239 (1991).
186. R. A. Lake and M. J. Owen, Transfection of the chloramphenicol-acetyltransferase gene into eu-karyotic cells using diethylaminoethyl (DEAE)-dextran, Methods Mol. Biol., 7, 23 (1991).
187. A. N. de Belder and K. Granath, Preparation and properties of fluorescein-labelled dextrans, Carbohydr. Res., 30, 375 (1973).
188. G. Rutili, Transport of macromolecules in subcutaneous tissue studied by FITC-dextrans, Dissertation, University of Uppsala, 1978.
189. J. Björk, R. F. del Maestro, and K. E. Arfors, Evidence for the participation of hydroxy radical in increased microvascular permeability, Agents Actions Suppl, 7, 208 (1980).
190. J. Björk and G. Smedegard, The microvasculature of the hamster cheek pouch as a model for studying acute immune-complex induced inflammatory reactions, Int. Arch. Allergy Appl. Immunol, 74, 178 (1984).
191. E. Svensjo, M. Erlansson, and G. C. van den Bos, Endotoxin-induced increase in leukocyte adherence and macromolecular permeability of postcapillary venules, Agents Actions, 29, 21 (1990).
192. F. Berthiaume, R. M. Ezzell, M. Toner, M. L. Yarmush, and R. G. Tompkins, Transport of fluorescent dextrans across the rat ileum after cutaneous thermal injury, Crit. Care Med., 22, 455 (1994).
193. N. Pantzar, B. R. Westrom, A. Luts, and S. Lundin, Regional small-intestinal permeability in vitro to different-sized dextrans and proteins in the rat, Scand. J. Gastroenterol, 28, 205 (1993).
194. W. G. Mayhan and W. L. Joyner, Permeability of blood-brain barrier to various sized molecules, Am. J. Physiol, 248, H712(1985).
195. K. Morimoto, T. Nakamura and K. Morisaka, Effect of medium-chain fatty acid salts on penetration of a hydrophilic compound and a macromolecular compound across rabbit corneas, Arch. Int. Phar-macodyn. Ther., 302, 18 (1989).
196. J. E. Pederson and H. L. Cantrill, Experimental retinal detachment. V. Fluid movement through the retinal hole, Arch. Ophthalmol, 102, 136 (1984).
197. C. Larsen, Dextran prodrugs: structures and stability in relation to therapeutic activity, Adv. Drug Delivery Rev., 3, 103 (1989).
198. A. D. Virnik, K. P. Khomyakov, and I. F. Skokova, Dextran and its derivatives, Russ. Client. Rev., 44, 1280 (1975).
199. L. Molteni, Dextran as drug carriers, Drug Carriers in Biology and Medicine (G. Gregoriadis, ed.) Academic Press, London, 1979, p. 107.
200. E. Schacht, R. Vercauteren, and S. Vansteenkiste, Some aspects of the application of dextran in prodrug design, J. Bioact. Compat. Polym., 3, 72 (1988).
201. S. Li, X. Y. Zhang, S. Y. Zhang, X. T. Chen, Y. H. Shu, J. L. Zhang, and D. M. Fan, Preparation of antigastric cancer monoclonal antibody MGb2-mitomycin C conjugate with improved antitumor activity, Bioconjug. Chem., 1, 245 (1990).
202. L. B. Shih, D. M. Goldenberg, H. Xuan, H. L. Sharkey and T. C. Hall, Anthracycline immunoconju-gates prepared by a site-specific linkage via an amino-dextran intermediate carrier, Cancer Res., 51, 4192 (1991).
203. Z. Brich, S. Ravel, T. Kissel, J. Fritsch, and A. Schoffman, Preparation and characterisation of a water soluble dextran immunoconjugate of doxorubicin and the monoclonal antibody (ABL 364), J. Controlled Release, 19, 245 (1992).
204. B. Schechter, R. Arnon, J. Schlessinger, E. Hurwitz, E. Aboub-pirak, and M. Sela, Indirect immuno-targetting of cis-Pt to human epidermoid carcinoma KB using the avidin-biotin system, Int. J. Cancer, 48, 167 (1991).
205. A. Bernstein, E. Hurwitz, R. Maron, M. Sela, and M. Wilchek, Higher antitumor efficacy of dauno-mycin when linked to dextran: in vivo and in vitro studies, J. Natl. Cancer Inst., 60, 379 (1978).
206. T. Kojima, M. Hashida, S. Muranishi, and H. Sezaki, Mitomycin C-dextran conjugate: a novel high molecular weight pro-drug of mitomycin C, J. Pharm. Pharmacol., 32, 30 (1980).
207. H. Onishi and T. Nagai, Preparation of dextran T70-methotrexate conjugate and dextran T70-mycophenolic acid conjugate, and in vitro effect of dextran T70-methotrexate on dihydrofolate reductase, Chem. Pharm. Bull., 34, 2561 (1986).
208. M. Hashida, R. Atsumi, K. Nishida, S. Nakane, Y. Takakura, and H. Sezaki, Biliary excretion of mitomycin C dextran conjugates in relation to physicochemical characteristics of carrier dextran, J. Pharmacobiodyn., 13, 441 (1990).
209. W. Richter and L. Kagedal, Preparation of dextran-protein conjugates and studies of their immunogenicity, Int. Arch. Allergy Appl. Immunol, 42, 887 (1972).
210. M. Azori, J. Pato, E. Csa’kvari, and F. Tudos, Polymeric prodrugs. 5. Dextran bound antirheumatic agent naproxen, Makromol. Chem., 187, 2073 (1986).
211. C. Larsen, Dissertation, Danish School of Pharmacy, Copenhagen, 1990.
212. E. Harboe, M. Johansen, and C. Larsen, Macromolecular prodrugs. VI. Coupling of Naproxen to dextrans and in vitro characterisation of the conjugates, Farmaci Sci. Ed., 16, 73 (1988).
213. C. Larsen and P. Kurtzhals, Preliminary studies on the in vivo fate of FITC dextrans and naproxen dextran ester prodrugs administered i.v. to rabbits, Acta Pharm. Nord., 1, 201 (1989).
214. C. Larsen, E. Harboe, M. Johansen, and H. P. Olesen, Macromolecular prodrugs. XVI. Colon-targeted delivery: comparison of the rate of release of naproxen from dextran ester prodrugs in ho-mogenates of various segments of the pig gastrointestinal (GI) tract, Pharm. Res., 6, 995 (1989).
215. S. Jacobsson and U. Rothman, Chromatography in wounds: use of carbohydrate polymer beads as wound cleansing agents, lRCSLibr. Compend., 1, 3.11.7 (1973).
216. S. Jacobsson, U. Rothman, G. Arturson, K. Ganrot, H. Haeger, and I. Juhlin, A new principle for the cleansing of infected wounds, Scand. J. Plast. Reconstr. Surg., 10, 65 (1976).
217. C. H. Flodén and K. Wikström, Controlled clinical trial with dextranomer (Debrisan) on venous leg wounds, Curr. Ther. Res., 24, 753 (1978).
218. A. J. Howcroft, A controlled trial of Dextranomer (Debrisan) in burns of the hand, Burns, 6,12 (1979).
219. C. A. Blanckmeister and D. H. Sussdorf, Macrophage activation by cross-linked dextran, J. Leukocyte Biol, 37, 209 (1985).